Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Oral Ivermectin for Genital Warts
Sponsor: University of Health Sciences Lahore
Summary
This study aims to evaluate the efficacy and safety of oral ivermectin in adults with recalcitrant genital warts that have not responded to conventional treatments. A total of 90 participants will receive oral ivermectin (200 µg/kg) once weekly for four weeks. Treatment response will be assessed by changes in wart number and size at weeks 2, 4, and 8. Potential adverse effects, recurrence, and patient satisfaction will also be evaluated. The study will help assess the potential role of oral ivermectin in treating persistent or recurrent genital warts.
Official title: Efficacy And Safety Of Oral Ivermectin For The Treatment Of Genital Warts
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2027-02-20
Completion Date
2027-11-01
Last Updated
2026-11-03
Healthy Volunteers
No
Conditions
Interventions
Ivermectin
Oral ivermectin administered at a dose of 200 µg/kg body weight once weekly for four weeks to adults with recalcitrant or recurrent genital warts that have not completely responded to conventional treatment. Treatment efficacy and safety will be assessed at baseline and at weeks 2, 4, and 8 by evaluating wart number and size, treatment response, new lesions, recurrence, patient satisfaction, and adverse effects. Copy
Locations (1)
Madinah Teaching Hospital, Faisalabad
Faisalābad, Punjab Province, Pakistan